News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Conference News AHA 2021 An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops Shelley Wood November 15, 2021
News Daily News Could an App Replace Statin Prescribing by Doctors? Michael O'Riordan September 08, 2021
News Conference News ESC 2021 New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT Shelley Wood August 28, 2021
News Daily News Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care Shelley Wood May 27, 2021
News Daily News FDA Approves Vericiguat for High-risk Patients With HF Michael O'Riordan January 20, 2021
News Daily News Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors Shelley Wood September 30, 2020
News Daily News VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks Michael O'Riordan September 24, 2020
News Conference News ACC 2020 A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA Michael O'Riordan March 28, 2020
News Daily News VICTORIA Trial of Vericiguat for Worsening HF Meets Primary Endpoint Todd Neale November 20, 2019